Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on July 7, 2025, covering an event that occurred on July 7, 2025, and announced via press release on July 8, 2025. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol "CTXR".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
The primary material event reported is the Company's regained compliance with Nasdaq Listing Rule 5550(a)(2). The Listing Qualifications Staff of The Nasdaq Stock Market LLC issued a written notice of compliance stating that for 10 consecutive trading days (June 20, 2025, to July 3, 2025), the closing bid price of the Company's common stock was at $1.00 per share or greater. Consequently, Nasdaq has considered this matter closed.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or new risk factors. The resolution of the listing compliance issue removes the immediate risk of delisting associated with the minimum bid price requirement.
Key Facts for Investor Verification
- Verify the current trading price of CTXR to ensure continued compliance with the $1.00 minimum bid price requirement.
- Confirm the status of the Nasdaq compliance notice via the attached press release (Exhibit 99.1).
- Review subsequent filings for any updates on the Company's financial position, as this 8-K contains no financial data.